AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Cantor Fitzgerald has initiated coverage on AbbVie Inc (NYSE:ABBV), a global pharma company.
坎托·菲茨杰拉德已开始对全球制药公司艾伯维公司（纽约证券交易所代码：ABBV）进行报道。
The analyst notes that the company has positioned itself to absorb Humira biosimilar erosion and achieve modest operational revenue growth.
分析师指出，该公司已将自己定位为吸收Humira生物仿制药的侵蚀并实现适度的运营收入增长。
Related: Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook.
相关： 前Humira增长平台推动了AbbVie第一季度的业绩，制药商上调了年度利润展望。
Cantor expects robust growth to resume in 2025, with projections aligning with management's long-term guidance of a high single-digit compound annual growth rate (CAGR) from 2024 to 2029.
坎托预计，2025年将恢复强劲增长，预测与管理层的长期指导一致，即从2024年到2029年将实现较高的个位数复合年增长率（CAGR）。
This forecast follows one of the largest losses of exclusivity (LOE) in the pharmaceutical industry.
该预测是在制药行业最大的独家经营权（LOE）损失之一之后作出的。
The analyst has initiated the coverage with an Overweight rating, with a price target of $200.
该分析师以增持评级启动了报道，目标股价为200美元。
Cantor expects that Bristol-Myers Squibb Co (NYSE:BMY), which acquired Karuna Therapeutics' KarXT, will likely come to market before AbbVie's antipsychotic emraclidine and become the leading drug.
坎托预计，收购Karuna Therapeutics的KarXt的百时美施贵宝公司（纽约证券交易所代码：BMY）很可能会在艾伯维的抗精神病药物依姆拉利定之前上市，成为领先的药物。
The analyst notes that if emraclidine's Phase 2 studies show a similar reduction in PANSS to what was seen in Phase 1, physicians think that emraclidine will win over KarXT.
分析师指出，如果emraclidine的2期研究显示PANSS的下降幅度与第一阶段相似，那么医生认为依姆拉利定将战胜KarXT。
Positive and Negative Syndrome Scale (PANSS) is used to assess antipsychotic treatment efficacy.
阳性和阴性综合征量表（PANSS）用于评估抗精神病药物治疗的疗效。
"When we compare the two products, we believe emraclidine differentiates by its dosing frequency (QD vs. BD), better GI safety profile, and potentially greater efficacy (PANSS score)," Cantor writes.
坎托写道：“当我们比较这两种产品时，我们认为依姆拉利定的区别在于其给药频率（QD 与 BD）、更好的胃肠道安全性以及可能更高的疗效（PANSS评分）。”
The analyst says the peak sales potential of Skyrizi, Rinvoq, emraclidine, and AbbVie's pipeline is underappreciated, and Humira's tail will be manageable at $4 billion—$5 billion in annual sales.
这位分析师表示，Skyrizi、Rinvoq、emraclidine和AbbVie产品线的峰值销售潜力被低估了，而Humira的尾巴将保持在40亿美元至50亿美元的年销售额水平。
AbbVie is advancing its second wave of Rinvoq development programs, with Phase 3 studies ongoing for five new indications: giant cell arteritis, lupus, hidradenitis suppurativa, alopecia areata, and vitiligo.
艾伯维正在推进其第二波Rinvoq开发计划，目前正在对五种新适应症进行三期研究：巨细胞动脉炎、狼疮、化脓性汗腺炎、脱发和白癜风。
The company expects to release data from these studies within the next three years. These new indications could generate several billion dollars in peak sales, indicating substantial growth potential for Rinvoq beyond 2027.
该公司预计将在未来三年内发布这些研究的数据。这些新迹象可能带来数十亿美元的峰值销售额，表明Rinvoq在2027年以后的巨大增长潜力。
Price Action: ABBV shares were up 1.10% at $166.16 at last check on Friday.
价格走势：周五最后一次查看时，ABBV股价上涨1.10％，至166.16美元。
Photo via Company
照片来自公司